i-ImmunDx™ enhances clinical diagnostics, supports disease management, and advances scientific research into ocular conditions, contributing significantly to precision medicine.
LTA-POC
Quantifying Immune Balance in Dry Eye Disease
The LTA-POC is a rapid, quantitative immunoassay developed to measure Lymphotoxin-α (LTA) levels in human tear samples.
Utilizing Seinda’s proprietary i-ImmunDx™ Analyzer, this test provides clinicians with precise insights into ocular surface immune homeostasis, facilitating accurate diagnosis and patient stratification in dry eye disease (DED).
Clinical Significance:
LTA plays a pivotal role in maintaining ocular immune tolerance by activating regulatory T cells (Tregs) through the TNFR2 pathway. Reduced LTA levels in tears have been associated with disrupted immune homeostasis, a key factor in the pathogenesis of DED. By quantifying LTA, the LTA-POC test aids in identifying patients with immune-mediated DED, supporting personalized treatment strategies and monitoring therapeutic efficacy.
Key Features:
- Rapid Results: Delivers quantitative measurements within 10–15 minutes at the point of care.
- High Sensitivity and Specificity: Detects LTA concentrations as low as 1 picogram, ensuring reliable assessment of immune status.
- Minimal Sample Requirement: Requires only 1–2 µL of tear fluid, enhancing patient comfort and ease of collection.
- Integrated Quality Control: Each test cassette contains a unique barcode, enabling the i-ImmunDx™ Analyzer to automatically apply the correct calibration and protocol, ensuring test integrity and eliminating the need for manual updates when new tests are introduced.
Why Choose LTA-POC:
Traditional diagnostic methods for DED often lack specificity and fail to correlate with disease severity. The LTA-POC test addresses this gap by providing objective, molecular-level data on immune status, enabling clinicians to differentiate between DED subtypes and tailor interventions accordingly.
For more information, please contact us at sales@seindabio.com.
LTA-POC Brochure
Rapid Detection of Allergic Conjunctivitis
The IgE-POC is a point-of-care diagnostic test developed to measure total Immunoglobulin E (IgE) levels in tear fluid—offering a rapid, objective solution for the detection and assessment of allergic conjunctivitis.Designed for use with the i-ImmunDx™ Analyzer, this test enables clinicians to confirm allergy-related inflammation in minutes, improving diagnostic accuracy and supporting more targeted treatment decisions.
Clinical Value:
Allergic conjunctivitis can be difficult to distinguish from other forms of ocular surface inflammation based on symptoms alone. The IgE-POC test provides molecular-level confirmation, helping clinicians differentiate allergic from non-allergic causes of eye irritation and enabling more precise treatment planning—including appropriate use of antihistamines or anti-inflammatory therapies.
Key Features:
- Fast Turnaround:
Quantitative results available within 10–15 minutes at the point of care. - High Sensitivity:
Accurately detects tear IgE levels, even at low concentrations, allowing for early identification of allergic responses. - Small Sample Volume:
Requires only 1–2 µL of tear fluid, ensuring patient comfort and efficient workflow. - Integrated Quality Control:
Each test cassette contains a unique barcode, enabling the i-ImmunDx™ Analyzer to automatically apply the correct calibration and protocol, ensuring test integrity and eliminating the need for manual updates when new tests are introduced.
Why Choose IgE-POC:
- Objective confirmation of allergy-related eye disease
- Supports differential diagnosis in multifactorial dry eye or ocular discomfort
- Simple, quick, and deployable in routine clinical practice
For more information, please contact us at sales@seindabio.com
IgE-POC Brochure
Inflammation Assessment for Dry Eye Disease
The MMP9-POC test is a quantitative point-of-care assay designed to detect Matrix Metalloproteinase-9 (MMP9) in tear fluid—a critical biomarker associated with ocular surface inflammation in Dry Eye Disease (DED).
Used with the i-ImmunDx™ Analyzer, the test provides clinicians with a rapid and objective tool to assess inflammatory status, improving diagnostic precision and treatment guidance.
Clinical Value:
MMP9 is an enzyme linked to the breakdown of corneal epithelial barrier function and inflammation in DED. Elevated levels are associated with more severe disease and poorer ocular surface health. The MMP9-POC test supports:
- Differentiating inflammatory from non-inflammatory DED
- Monitoring treatment response over time
- Informing anti-inflammatory therapeutic decisions
Key Features:
- Rapid Quantitative Results:
Delivers actionable inflammation data in just 10-15 minutes at the point of care. - High Sensitivity & Precision:
Detects subtle elevations in MMP9 that may not be evident through symptoms alone, enabling early and accurate intervention. - Low Sample Volume:
Requires only 1-2 uL of tear fluid, minimizing discomfort and streamlining the workflow. - Integrated Quality Control:
Each test cassette contains a unique barcode, enabling the i-ImmunDx™ Analyzer to automatically apply the correct calibration and protocol, ensuring test integrity and eliminating the need for manual updates when new tests are introduced. - Built-in Safety & Quality Checks:
Each test run includes internal controls to verify result integrity and analyzer performance.
Why Choose MMP9-POC:
- Provides real-time, objective inflammation status
- Enhances DED subtyping and personalized care
- Seamless integration into any eye care practice with minimal training
For more information, please contact us at sales@seindabio.com.
MMP9-POC Brochure
Launching in 2026
Launching in 2026